Who can administer
  
                  May be administered by registered competent doctor or nurse/midwife
      
  
        Important information
  
                  
- Unlicensed preparation
 
- Must be diluted before administration via IV infusion. High peak levels increase risk of damage to eyesight so DO NOT GIVE undiluted
 
      
  
        Available preparations
  
                  EMB-Fatol 1g in 10ml vial
      
  
        Reconstitution
  
                  Already in solution
Dilute further prior to administration
      
  
        Infusion fluids
  
                  Sodium chloride 0.9% or Glucose 5%
      
  
        Methods of intravenous administration
  
                  Slow intravenous infusion
- Add required dose to 500ml infusion solution and administer over at least 2 hours (ref 1)
 
- Slow infusion required, as high peak levels increase risk of damage to eyesight
 
      
  
        Dose in adults
  
                  Usual dose
- Use the same dose by intravenous infusion as would be given orally
 
- Switch to oral therapy as soon as possible
 
Renal impairment (ref 2,3)
| GFR (mL/min/1.73m2) | 
Dose | 
| 30 or more | 
Usual dose | 
| Less than 30 | 
15 to 25mg/kg (max 2.5g) three times per week | 
      
  
        Monitoring
  
                  
- Hypersensitivity syndrome has been reported (skin reaction, eosinophilia plus one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, pericarditis). Fever and lymphadenopathy may be present.
 
- Anaphylactoid reactions have been reported
 
- Ethambutol can cause optic neuritis and must be discontinued in patients who report changes in their eyesight, as it can cause irreversible visual damage (blindness) if treatment is not discontinued in a timely manner.
 
- Monitor renal and hepatic function
 
      
  
        Storage
  
                  Store below 250C
      
  
        References
  
                  1: Medusa UK Injectable Medicines guide downloaded 28/07/2025
2: Renaldrugdatabase.com, downloaded 28/07/2025
3. Sanford guide, downloaded 28/07/2025
      
  
        Therapeutic classification
  
                  Anti-tuberculosis agent